Enjoy complimentary customisation on priority with our Enterprise License!
The global beta lactam and beta lactamase inhibitors market size is estimated to grow by USD 10.06 billion, at a CAGR of 5.47% between 2023 and 2028. It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historical data from 2018-2022, besides analyzing the current market scenario.
Antimicrobial resistance poses a growing challenge to traditional antibiotics, particularly beta lactams. To combat resistance, there's a rising demand for beta lactamase inhibitors used alongside beta lactam antibiotics. Pharmaceutical companies invest in developing novel inhibitors and modifying existing antibiotics to enhance efficacy against resistant bacteria. Healthcare providers increasingly adopt combination therapies targeting multiple resistance mechanisms, driving demand for these inhibitors. Antimicrobial resistance prolongs hospital stays, increases healthcare costs, and raises mortality rates, underscoring the need for effective treatments. Despite higher drug costs, the economic impact of untreated infections supports the use of combination therapies, fueling growth in the market.
To learn more about this market report, Download Report Sample
In the pharmaceutical sphere, beta-lactamase inhibitors play a pivotal role, particularly in tandem with cephalosporin antibiotics, making them crucial revenue contributors within the cephalosporin segment. With an aging population and rising incidence of chronic diseases, the demand for effective prescription drugs is escalating, signaling significant future market potential. Tailoring strategies to region-specific plans necessitates extensive analysis and quantitative analysis to gauge market dynamics and ensure a robust competitive outlook. As innovation drives progress, strategic business strategy are imperative for harnessing the full potential of beta-lactamase inhibitors, especially in the oral segment.
The market share growth by the oral segment will be significant during the forecast period. The rise of antibiotic-resistant bacterial strains, including those producing beta lactamase enzymes, increases the demand for effective oral antibiotics and beta lactamase inhibitors. As bacterial resistance continues to evolve and spread, there is a need for novel oral therapies capable of overcoming resistance mechanisms and effectively treating infections. The efficacy, safety, and tolerability of oral beta lactam antibiotics and beta lactamase inhibitors influence prescribing patterns and patient preferences.
Get a glance at the market contribution of various segments Download the PDF Sample
The oral segment was valued at USD 12.59 billion in 2018. Further, the convenience of oral administration and patient compliance are important considerations in antibiotic therapy. Oral formulations offer ease of administration, allowing patients to self-administer medication at home without the need for hospitalization or invasive procedures. Patient adherence to treatment regimens is essential for achieving optimal outcomes and preventing antibiotic resistance. Thus, these factors will drive the growth of the oral segment of the market during the forecast period.
The cephalosporins segment will account for the largest share of this segment.?The rise of antibiotic-resistant bacteria, including beta-lactamase-producing strains, fuels the demand for potent antibiotics like cephalosporins. These drugs are crucial in treating a wide range of infections caused by resistant Gram-positive and Gram-negative bacteria. Cephalosporins offer broad-spectrum antibacterial activity, making them versatile options for various infections. Recognized for their efficacy and safety, cephalosporins are widely used in both community and hospital settings, including the treatment of healthcare-associated infections (HAIs). Market leaders like GlaxoSmithKline plc and Merck KGaA offer cephalosporin options for oral administration, driving the market growth during the forecast period.
The penicillins segment is also showing steady growth during the forecast period. Penicillins are versatile antibiotics effective against a wide range of bacterial infections, including respiratory, skin, urinary, and sexually transmitted infections. Their bactericidal action, safety profile, and well-established efficacy make them valuable options in both community and hospital settings. Despite being one of the oldest antibiotic classes, penicillins remain essential due to their effectiveness against various pathogens. Market leaders like Pfizer Inc. and Novartis AG offer penicillin formulations such as amoxicillin, driving the market growth during the forecast period.
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 35% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The aging population in North America is more susceptible to infections, requiring effective antimicrobial treatments. As the elderly population grows, there is an increased demand for antibiotics, including beta lactam and beta lactamase inhibitor combinations, to manage age-related infections and associated comorbidities.
Moreover, North America boasts advanced healthcare infrastructure, including well-equipped hospitals, research facilities, and pharmaceutical companies. This facilitates the development, manufacturing, and distribution of beta lactam antibiotics and beta lactamase inhibitors, contributing to regional market growth. Additionally, North America has one of the highest healthcare expenditures globally, with significant spending on pharmaceuticals. Thus, these factors will propel the growth of the regional market during the forecast period.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
Alkem Laboratories Ltd., Astellas Pharma Inc., Cipla Ltd., GlaxoSmithKline Plc, Jaiwik Biotech, Lupin Ltd., MedPlus Health Services Ltd., Meiji Holdings Co. Ltd., Merck KGaA, Novartis AG, Numera Life Sciences, Pfizer Inc., Sandoz AG, Sanofi SA, Spero Therapeutics, Taj Pharmaceutical Ltd., Zeelab Laboratories Ltd., Abbott Laboratories, and F. Hoffmann La Roche Ltd.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
In the realm of pharmaceuticals, beta-lactamase inhibitors stand as a potent antibacterial agent. Often used in conjunction with cephalosporin antibiotics, they exhibit promising results in combating drug-resistant bacteria. Monobactam derivatives are undergoing rigorous clinical trials, positioning themselves as formidable contenders in the battle against infectious diseases. As a significant revenue contributor within the cephalosporin segment, these inhibitors play a pivotal role in addressing a myriad of chronic diseases. Market forecasts and estimations underscore their future potential, with region-specific plans shaping their competitive outlook. The landscape demands extensive analysis and strategic business initiatives to harness their full therapeutic capabilities. There are multiple factors influencing market growth analysis. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges.
Rising focus on novel drug development is the key factor driving the market. Pharmaceutical companies are investing in research and development efforts to discover and develop next-generation beta lactam antibiotics and beta-lactamase inhibitors with improved efficacy, a broader spectrum of activity, and enhanced resistance profiles. Novel drug candidates are being designed to overcome resistance mechanisms and target resistant bacterial strains, addressing unmet medical needs in infectious disease management.
Additionally, there is a growing interest in developing targeted therapies and precision medicine approaches for infectious diseases, including beta-lactam-resistant infections. Researchers are exploring novel drug targets, therapeutic strategies, and combination therapies to enhance treatment outcomes and minimize the emergence of resistance. Beta-lactamase inhibitors are being investigated as adjuvant therapies to restore the activity of beta-lactam antibiotics against resistant pathogens. Thus, the rising focus on novel drug development will boost market growth during the forecast period.
Technological advancements in antibiotic discovery is the primary trend shaping the market. Technological advancements in antibiotic discovery accelerate the identification, optimization, and development of beta lactamase inhibitors to address the challenges of antimicrobial resistance and infectious diseases. Computational modeling techniques, such as molecular docking and virtual screening, enable researchers to predict the binding interactions between beta-lactam antibiotics, beta lactamase inhibitors, and bacterial targets. Structure-based design approaches leverage this knowledge to design and optimize new molecules with enhanced activity against drug-resistant bacteria.
Additionally, functional genomics studies elucidate the biological functions of bacterial genes involved in antibiotic resistance, providing insights into potential drug targets and strategies to overcome resistance. Furthermore, metagenomics techniques enable the study of microbial communities in diverse environments, such as soil and marine ecosystems, to identify novel antibiotic-producing microorganisms and their biosynthetic gene clusters. Furthermore, microfluidic platforms and lab-on-a-chip devices enable the miniaturization and automation of antibiotic screening assays, allowing for rapid and cost-effective drug discovery workflows. Thus, technological advancements in antibiotic discovery will propel market growth during the forecast period.
The emergence of carbapenem-resistant Enterobacteriaceae (CRE) is the major challenge for the market expansion. CRE strains are resistant to carbapenem antibiotics, which are often considered last-resort treatments for serious bacterial infections. The emergence of CRE limits treatment options for healthcare providers, leading to challenges in managing infections caused by these multidrug-resistant pathogens. Infections caused by CRE are associated with higher rates of mortality and morbidity compared with susceptible bacterial strains. Moreover, CREs are commonly associated with healthcare settings, including hospitals, long-term care facilities, and intensive care units. Nosocomial transmission of CREs among patients can lead to outbreaks and healthcare-associated infections, further complicating infection control efforts and increasing the risk of dissemination within healthcare facilities.
Moreover, CREs have been reported worldwide, with outbreaks occurring in various regions, such as West Africa and South Africa. The global spread of CRE strains, facilitated by international travel and healthcare-associated transmission, highlights the need for coordinated surveillance and control measures to prevent the further dissemination of these resistant pathogens. Furthermore, controlling the spread of CRE within healthcare settings presents challenges due to the ability of these bacteria to survive on environmental surfaces and persist in healthcare-associated reservoirs. Stringent infection control measures, including hand hygiene, environmental cleaning, and patient isolation, are essential to prevent CRE transmission and outbreaks. Thus, the presence of CRE will decline market growth during the forecast period.
The market research and growth report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market growth and forecasting report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Customer Landscape
The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
In the realm of healthcare, market inhibitors are instrumental in combating a spectrum of infections like urinary tract infection, respiratory infection, and skin infection. They are pivotal in addressing challenging scenarios such as nosocomial pneumonia and blood stream infection, including hospital acquired pneumonia. Despite regulatory approval delays, the market shows promising future estimations due to increasing infectious disease prevalence. However, navigating this landscape requires addressing product satisfaction and understanding the competitive nature characterized by fragmentation dominance and amalgamation traits. Notable recent significant developments underscore the importance of market penetration and market development, with leading vendors like Creative Diagnostics spearheading innovation.
Further, monobactam derivatives are undergoing rigorous clinical trials, positioning themselves as formidable contenders in the battle against infectious diseases. As a significant revenue contributor within the cephalosporin segment, these inhibitors play a pivotal role in addressing a myriad of chronic diseases. Market forecasts and estimations underscore their future potential, with region-specific plans shaping their competitive outlook. The landscape demands extensive analysis and strategic business initiatives to harness their full therapeutic capabilities.
Market Scope |
|
Report Coverage |
Details |
Page number |
179 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 5.47% |
Market Growth 2024-2028 |
USD 10.06 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
4.73 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 35% |
Key countries |
US, Germany, UK, China, and India |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
AbbVie Inc., Alkem Laboratories Ltd., Astellas Pharma Inc., Cipla Ltd., GlaxoSmithKline Plc, Jaiwik Biotech, Lupin Ltd., MedPlus Health Services Ltd., Meiji Holdings Co. Ltd., Merck KGaA, Novartis AG, Numera Life Sciences, Pfizer Inc., Sandoz AG, Sanofi SA, Spero Therapeutics, Taj Pharmaceutical Ltd., Zeelab Laboratories Ltd., Abbott Laboratories, and F. Hoffmann La Roche Ltd. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market forecasting condition analysis for the forecast period. |
Customization purview |
If our market forecast report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download the Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Route of Administration
7 Market Segmentation by Drug Class
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.